BCL2 and neoplasm: The results of network pharmacology and molecular docking analyses suggested that SSA may interact with BCL2, ESR1, HIF1A, and STAT3 as well as PI3K/AKT signalling pathways and inhibit tumour growth by promoting apoptosis.